BioSpectator Reporter Jeongmin Jo
Combining stem cell application tecnología and pain control tecnología to jointly develop tratamientos for major spinal diseases including degenerative disc disease and spinal cord injury
CHA University Bundang CHA Hospital anunció el 18th that it has firmó un business acuerdo with RudaCure, a company developing tratamientos for dolor neuropático, for the 'desarrollo of spinal disease regenerative therapeutics.'
Basándose en esto acuerdo, Bundang CHA Hospital and RudaCure will combine Bundang CHA Hospital's stem cell application regenerative tecnología with RudaCure's pain control tecnología to pursue: ▲ desarrollo of new spinal disease tratamientos with pain control and regenerative effects ▲ conducting ensayo clínicos of jointly developed tratamientos at Bundang CHA Hospital ▲ new drug aprobación based on joint ensayo clínicos ▲ joint transferencia de tecnología and desarrollo de nuevos fármacos for industrialization of spinal disease tratamientos.
Jaehua Kim, Director of Bundang CHA Hospital, declaró, "A través de esto acuerdo between Bundang CHA Hospital, which has strengths in stem cell investigación for major spinal diseases such as degenerative disc disease and spinal cord injury, and RudaCure, which specializes in tratamiento del dolor desarrollo de nuevos fármacos, we look forward to creating cases of innovador tratamiento tecnología for spinal diseases."